MDGL

Is IVA a good stock to buy? We came across a bullish thesis on Inventiva S.A. on BioEquity Watch’s Substack.

Madrigal (MDGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BridgeBio Pharma (BBIO), Madrigal Pharmaceuticals (MDGL) and Cytokinetics (CYTK) traded meaningfully

Madrigal Pharmaceuticals event puts genetics in focus Madrigal Pharmaceuticals (MDGL) drew fresh attention after publishing a secondary analysis of its Phase 3 MAESTRO-NASH trial, indicating that Rezdiffra’s liver benefits appeared consistent across several…

Madrigal Pharmaceuticals has delivered a very large 5 year gain for shareholders, and after that kind of rise the obvious question is whether the current share price still lines up with what the business is generating in sales today.

Madrigal Pharmaceuticals recently reported in the Journal of Hepatology that a pre-specified secondary analysis of the Phase 3 MAESTRO-NASH trial found Rezdiffra (resmetirom) improved fibrosis, MASH resolution, liver fat and biomarker levels across patients…

Secondary analysis of the Phase 3 MAESTRO-NASH trial demonstrated Rezdiffra improved histology and MRI-PDFF across common genetic variants associated with MASH progression CONSHOHOCKEN, Pa., Oct.

Madrigal has a first-mover advantage in treating MASH, a type of fatty liver disease.